We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

64 hedge funds and large institutions have $67.4M invested in Matinas BioPharma in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 7

306% more capital invested

Capital invested by funds: $16.6M → $67.4M (+$50.8M)

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

73% more funds holding

Funds holding: 37 → 64 (+27)

0.04% more ownership

Funds ownership: 0.32% → 0.37% (+0.04%)

Holders
64
Holders Change
+27
Holders Change %
+72.97%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
11
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.61M
2
BBA
Baker Bros. Advisors
New York
+$750K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$678K
4
ECM
ExodusPoint Capital Management
New York
+$549K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$356K

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$946K
2
Millennium Management
Millennium Management
New York
-$341K
3
Victory Capital Management
Victory Capital Management
Texas
-$337K
4
TI
Telemetry Investments
New York
-$272K
5
LTFS
Ladenburg Thalmann Financial Services
Florida
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$214K -$341K -5,885 -76%
Goldman Sachs
27
Goldman Sachs
New York
$198K +$101K +1,742 New
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$188K +$96.2K +1,660 New
CDH
29
Charles D. Hyman
$181K – – –
PAG
30
Private Advisor Group
New Jersey
$154K -$7.76K -134 -9%
AGM
31
Alpine Global Management
New York
$138K +$70.6K +1,218 New
SIG
32
Sargent Investment Group
Maryland
$127K +$64.7K +1,117 New
BJL
33
Brighton Jones LLC
Washington
$114K – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$102K – – –
IWAG
35
Integer Wealth Advisors Group
Georgia
$82K +$67K +1,156 New
Charles Schwab
36
Charles Schwab
California
$80K – – –
Stifel Financial
37
Stifel Financial
Missouri
$78K +$40.6K +700 New
AWA
38
Arete Wealth Advisors
Illinois
$68K +$34.8K +600 New
CWM
39
CCG Wealth Management
California
$68K +$34.8K +600 New
Citadel Advisors
40
Citadel Advisors
Florida
$63K +$32.2K +556 New
DAS
41
Dynamic Advisor Solutions
Arizona
$47K – – –
RC
42
RegentAtlantic Capital
New Jersey
$45K +$23.2K +400 New
NRS
43
Neville Rodie & Shaw
New York
$40K – – –
Commonwealth Equity Services
44
Commonwealth Equity Services
Massachusetts
$40K +$1.16K +20 +6%
Morgan Stanley
45
Morgan Stanley
New York
$39K +$20K +346 New
State Street
46
State Street
Massachusetts
$38K +$19.4K +334 New
Janney Montgomery Scott
47
Janney Montgomery Scott
Pennsylvania
$34K +$17.4K +300 New
SBWIC
48
Schaper Benz & Wise Investment Counsel
Wisconsin
$32K +$16.6K +286 New
SPC
49
Sigma Planning Corp
Michigan
$29K +$14.8K +256 New
CFS
50
CRA Financial Services
New Jersey
$23K – – –
1
2
3

MTNB Hedge Fund Activity: Q4 2019 in Review

64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2019, worth a combined $67.4M — up 306% from $16.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new MTNB positions and 7 closed out — a net gain of 27 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $1.61M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $946K sold.

  • 64 institutional investors held Matinas BioPharma (MTNB) as of Q4 2019, up from 37 in Q3 2019.
  • Funds reported $67.4M of Matinas BioPharma stock for Q4 2019, up 306% quarter-over-quarter.
  • 34 funds opened new Matinas BioPharma positions in Q4 2019 and 7 closed out, a net change of +27 holders.
  • The largest Matinas BioPharma buyer in Q4 2019 was BlackRock, an estimated $1.61M added.
  • The largest Matinas BioPharma seller in Q4 2019 was Granite Point Capital Management, an estimated $946K sold.

Based on aggregated 13F filings for Q4 2019.